Effect of Tamsulosin versus Placebo in Females with Lower Urinary Tract Symptoms Less Than 40 Years of Age
Abstract
Introduction: LUTS in women chronically affects the quality of life, and, to combat it, few treatment methods are available to women below the age of 40. Tamsulosin is an alpha-1 adrenergic blocker commonly used in men whereas young women with LUTS are under-studied. Objective: To compare the average response of International Prostate Symptom Score (IPSS) due to treatment using Tamsulosin and Placebo in females less than 40 years and with LUTS after 4 weeks of treatment. Material and methods: This was a prospective, comparative cross-sectional study done in AFIU, Rawalpindi from 12th April, 2025 to 12th July, 2025. One hundred and thirty six patients were randomly assigned to take Tamsulosin 0.4 mg or placebo daily once in a period of 4 weeks. The scores of IPSS before and after treatment were noted and compared. Results: The improvement of the IPSS was substantially superior in the Tamsulosin group (7.9 + 2.8) than in the placebo (2.4 + 2.5; p < 0.001). It was a well-tolerated treatment. Conclusion: Tamsulosin is a safe and effective therapy of LUTS syndrome in young girls
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Luteolin rescues postmenopausal osteoporosis elicited by OVX through alleviating osteoblast pyroptosis via activating PI3K-AKT signaling
- Drugs Used in “Chemsex”/Sexualized Drug Behaviour—Overview of the Related Clinical Psychopharmacological Issues
- Luteolin Inhibits Dexamethasone‐Induced Osteoporosis by Autophagy Activation Through miR‐125b‐5p/SIRT3/AMPK/mTOR Axis, an In Vitro and In Vivo Study
- Cutting-edge insights into liver fibrosis: advanced therapeutic strategies and future perspectives using engineered mesenchymal stem cell-derived exosomes
- Can we predict and manage persistent storage and voiding LUTS following bladder outflow resistance reduction surgery in men? ICI‐RS 2023
- Chylomicron-mimicking supramolecular nano emulsion for oral luteolin delivery against hyperuricemia
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.